Lilly Ventures helps fund California research company

Lilly Ventures, the venture capital arm of Indianapolis-based Eli Lilly and Co. has co-led a $44 million round of financing for Cylene Pharmaceuticals Inc., the San Diego drug discovery company said today.
 
HBM BioVentures Ltd. of Switzerland lead the round. It is Lilly’s first investment in Cylene; it’s share of the financing was not disclosed.

Cylene plans to use the money to conduct a 500-patient Phase II human clinical trial of a treatment for drug-resistant cancer and develop two more products.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}